Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
B-cell Lymphoma
share announcement

B-cell Lymphoma

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".

Deadline for manuscript submissions: closed (30 January 2024) | Viewed by 4310

Special Issue Editors

Dr. Zijun Yidan Xu-Monette

E-Mail Website
Guest Editor
Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
Interests: B-cell lymphoma; biomarkers; molecular biology; genomics; gene expression; tumor microenvironment; epigenetics; prognostic prediction
Dr. Wenyu Shi

E-Mail Website
Guest Editor
Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China
Interests: lymphoma; leukemia
Dr. Yu Li

E-Mail Website
Guest Editor
Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, China
Interests: lymphoma; leukemia

Special Issue Information

Dear Colleagues,

B-cell lymphoma is a group of non-Hodgkin lymphoma transformed from normal B lymphocytes at various differentiation stages. B-cell lymphoma constitutes 85% of non-Hodgkin lymphoma which is the seventh most common type of cancer in the United States. Molecular biology of lymphomas, either tumor intrinsic or derived from the tumor microenvironment, is not only important for lymphoma diagnosis (such as MYC/BCL2/CCND1 gene rearrangements and MYD88 L265 mutation) and prognostic prediction, but also the key to uncover pathogenic mechanisms and identify therapeutic targets. For example, novel genetic models based on genetic drivers have been developed to classify diffuse large B-cell lymphoma (DLBCL), the most common type of B-cell lymphoma, which can be considered complementary to the GCB/ABC cell-of-origin classification based on normal B-cell gene-expression signatures maintained in lymphoma. Classification based on the lymphoma microenvironment characteristics is also being developed. Moreover, emerging single-cell sequencing technology has been applied in various types of B-cell lymphoma. Despite the sparsity, single-cell sequencing data have delineated molecular characteristics of distinct cell clusters and revealed deeper levels of biological heterogeneity for precision medicine. On the other hand, application of multiplexed imaging technology such as imaging mass cytometry reveals the spatial structure of the lymphoma immune microenvironment at the single-cell level. In B-cell lymphoma, we are also witnessing exciting advances in novel therapies changing clinical practice, including chimeric antigen receptor T-cell therapies and antibody-drug conjugates, as well as the promising bispecific T cell engager therapy. In this special edition, we welcome researches gaining new insights into lymphoma biology with implications for prognostic prediction, early detection, and therapy development.

Dr. Zijun Yidan Xu-Monette
Dr. Wenyu Shi
Dr. Yu Li
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • B-cell lymphoma
  • genomics
  • epigenetics
  • biomarker
  • targeted therapy
  • tumor microenvironement

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

11 pages, 570 KiB  
Article
B–NHL Cases in a Tertiary Pediatric Hematology—Oncology Department: A 20-Year Retrospective Cohort Study
by Ioannis Kyriakidis, Iordanis Pelagiadis, Maria Stratigaki, Nikolaos Katzilakis and Eftichia Stiakaki
Life 2024, 14(5), 633; https://doi.org/10.3390/life14050633 - 16 May 2024
Viewed by 466
Abstract
Non-Hodgkin lymphoma (NHL) is among the five most common pediatric cancer diagnoses in children and adolescents and consists of a heterogeneous group of lymphoid tissue malignancies –with B-cell-derived NHL accounting for nearly 80% of cases. Novel and high-throughput diagnostic tools have significantly increased [...] Read more.
Non-Hodgkin lymphoma (NHL) is among the five most common pediatric cancer diagnoses in children and adolescents and consists of a heterogeneous group of lymphoid tissue malignancies –with B-cell-derived NHL accounting for nearly 80% of cases. Novel and high-throughput diagnostic tools have significantly increased our understanding of B-NHL biology and molecular pathogenesis, leading to new NHL classifications and treatment options. This retrospective cohort study investigated 17 cases of both mature B-cell NHL (Burkitt lymphoma or BL; Diffuse large B-cell lymphoma or DLBCL; Primary mediastinal large B-cell lymphoma or PMBCL; Follicular lymphoma or FL) and immature B-cell progenitor NHL (B-lymphoblastic lymphoma or BLL) that were treated in a tertiary Pediatric Hematology-Oncology Department during the last 20 years. Modern NHL protocols for children, adolescents, and young adults, along with the addition of rituximab, are safe and efficient (100% overall survival; one relapse). Elevated ESR was more prevalent than elevated LDH. Analyses have focused on immune reconstitution (grade ≥3 infections, lymphocyte and immunoglobulin levels recovery) and body-mass-index changes post-treatment, late effects (in 53% of patients), and the presence of histology markers BCL2, BCL6, CD30, cMYC, and Ki-67%. One patient was diagnosed with a second malignant neoplasm (papillary thyroid cancer). Full article
(This article belongs to the Special Issue B-cell Lymphoma)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

12 pages, 2258 KiB  
Review
Primary Large B-Cell Lymphoma of Immune-Privileged Sites of the Cerebellum: A Case Series and Review of the Literature
by Saverio Pancetti, Daoud Rahal, Bethania Fernades, Carlo Galli, Silvia Uccella, Luigi Maria Terracciano, Federico Pessina, Lorenzo Bello and Arturo Bonometti
Life 2023, 13(1), 201; https://doi.org/10.3390/life13010201 - 10 Jan 2023
Viewed by 1829
Abstract
Primary large B-cell lymphoma of immune-privileged sites (IP-LBCL) is a rare malignant hematological neoplasm. Involvement of the cerebellum is even rarer and its diagnosis is often difficult to make due to its non-specific clinical and radiological presentation. Methods: We reported 3 cases of [...] Read more.
Primary large B-cell lymphoma of immune-privileged sites (IP-LBCL) is a rare malignant hematological neoplasm. Involvement of the cerebellum is even rarer and its diagnosis is often difficult to make due to its non-specific clinical and radiological presentation. Methods: We reported 3 cases of cerebellar IP-LBCL followed at our hospital and reviewed the medical literature to unravel the peculiarities of this poorly studied entity. Outcomes: Analyzing our cases and reviewing the literature, we could collect and study 26 cases of cerebellar IP-LBCL. To the best of our knowledge, this is the largest cohort of such patients currently published. Conclusion: Cerebellar IP-LBCL presents more often in adult females with cerebellum-related focal neurological signs such as ataxia, headache, and nausea. Histological confirmation is mandatory for a correct diagnosis and treatment and all cases feature diffuse large B-cell lymphoma histopathology. Compared to other encephalic IP-LBCL, cerebellar cases seem to include a higher number of cases with germinal center B-cell phenotype and better survival. These differences may be related to a different immune microenvironment and especially immunoregulation that distinguishes the cerebellum from other areas of the CNS. Full article
(This article belongs to the Special Issue B-cell Lymphoma)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

8 pages, 1345 KiB  
Case Report
A Rare B-Myeloid Conversion of Follicular Lymphoma into Clonally Related Acute Myeloid Leukemia: A Case Report
by Xiyue Yan, Juan Liu, Yu Ben, Weicheng Zheng, Pan Hu, Yaping Zhang and Wenyu Shi
Life 2023, 13(3), 729; https://doi.org/10.3390/life13030729 - 8 Mar 2023
Viewed by 1353
Abstract
Follicular lymphoma (FL) is a highly prevalent indolent lymphoma, and the risk of histological transformation is approximately 2–3% per year. Transformation of FL generally occurs in the same lineage (B cell lineage). Another rare form of disease progression is the transformation of neoplastic [...] Read more.
Follicular lymphoma (FL) is a highly prevalent indolent lymphoma, and the risk of histological transformation is approximately 2–3% per year. Transformation of FL generally occurs in the same lineage (B cell lineage). Another rare form of disease progression is the transformation of neoplastic B-cells to another cell lineage such as acute myeloid leukemia (AML). The low incidence of B-myeloid transformation associated with poor prognosis hinders the establishment of model systems to identify molecular mechanisms. A 64-year-old woman was diagnosed with FL and achieved a satisfactory response after six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Approximately one month after treatment terminated, the disease progressed to AML with an increased white blood cell count and abnormal coagulation. Interestingly, nucleotide sequence analysis of the genomic region encoding the immunoglobulin heavy-chain variable domain showed the possibility of homologous transformation from lymphoma to leukemia cells. Although the patient experienced transient improvement after undergoing treatment with one cycle of idarubicin and cytarabine combined with etoposide, she relapsed and died 8 days after venetoclax salvage therapy. Patient with B-myeloid transformation was associated with an aggressive clinical course and poor prognosis. Conventional strategies for treating histologically transformed AML were ineffective. However, treatment with a Bcl-2 inhibitor could serve as an option. Here we review the literature relevant to this rare histological transformation of FL. Full article
(This article belongs to the Special Issue B-cell Lymphoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop